PRELUDE THERAPEUTICS INC: capital expenditure payments
Capital expenditure payments for PRELUDE THERAPEUTICS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All PRELUDE THERAPEUTICS INC financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 67,000 | USD | 2026-03-10 | 10-K · 0001193125-26-099428 |
| 2024-01-01 | 2024-12-31 | 764,000 | USD | 2026-03-10 | 10-K · 0001193125-26-099428 |
| 2023-01-01 | 2023-12-31 | 3,513,000 | USD | 2025-03-10 | 10-K · 0000950170-25-035921 |
| 2022-01-01 | 2022-12-31 | 3,019,000 | USD | 2024-02-15 | 10-K · 0000950170-24-016016 |
| 2021-01-01 | 2021-12-31 | 2,323,000 | USD | 2023-03-15 | 10-K · 0000950170-23-007989 |
| 2020-01-01 | 2020-12-31 | 621,000 | USD | 2022-03-17 | 10-K · 0001564590-22-010723 |
| 2019-01-01 | 2019-12-31 | 780,000 | USD | 2021-03-16 | 10-K · 0001564590-21-013330 |
Related financial histories
- PRELUDE THERAPEUTICS INC: total assets
- PRELUDE THERAPEUTICS INC: total liabilities
- PRELUDE THERAPEUTICS INC: stockholders equity
- PRELUDE THERAPEUTICS INC: cash and cash equivalents
- PRELUDE THERAPEUTICS INC: net income or loss
- PRELUDE THERAPEUTICS INC: operating cash flow
- PRELUDE THERAPEUTICS INC: financing cash flow
- PRELUDE THERAPEUTICS INC: investing cash flow
- PRELUDE THERAPEUTICS INC: retained earnings or deficit
- PRELUDE THERAPEUTICS INC: basic weighted-average shares
- PRELUDE THERAPEUTICS INC: diluted weighted-average shares
- PRELUDE THERAPEUTICS INC: basic earnings per share
- PRELUDE THERAPEUTICS INC: diluted earnings per share
- PRELUDE THERAPEUTICS INC: net property, plant and equipment
- PRELUDE THERAPEUTICS INC: share-based compensation expense
- PRELUDE THERAPEUTICS INC: operating income or loss
- PRELUDE THERAPEUTICS INC: current assets
- PRELUDE THERAPEUTICS INC: current liabilities
- PRELUDE THERAPEUTICS INC: current accounts payable
- PRELUDE THERAPEUTICS INC: operating expenses
- PRELUDE THERAPEUTICS INC: research and development expense
Inspect the source
- Entity
- PRELUDE THERAPEUTICS INC / CIK 0001678660
- Captured
- 2026-09-19T11:20:17.942Z
- SEC response SHA-256
4023c74bc9e5c895b2ef77ae58b10f1e8765286041523a6da05c89cacba71998
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001678660.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))